Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 4:13:1057597.
doi: 10.3389/fimmu.2022.1057597. eCollection 2022.

Modulating the tumor immune microenvironment with locoregional image-guided interventions

Samagra Jain  1 , Rahul A Sheth  2
Affiliations
Review

Modulating the tumor immune microenvironment with locoregional image-guided interventions

Samagra Jain et al. Front Immunol. .

Abstract

Cancer immunotherapy has gained significant attention in recent years and has revolutionized the modern approach to cancer therapy. However, cancer immunotherapy is still limited in its full potential due to various tumor immune-avoidance behaviors and delivery barriers, and this is seen in the low objective response rates of most cancers to immunotherapy. A novel approach to immunotherapy utilizes image-guided administration of immunotherapeutic agents directly into a tumor site; this technique offers several advantages, including avoidance of potent toxicity, bypassing the tumor immunosuppressive microenvironment, and higher therapeutic bioavailability relative to systemic drug administration. This review presents the biological rationale for locoregional image-guided immunotherapy administration, summarizes the existing interventional oncology approaches to immunotherapy, and discusses emerging technological advances in biomaterials and drug delivery that could further advance the field of interventional oncology.

Keywords: cancer; image guidance; immunotherapy; interventional radiography; transarterial administration.

PubMed Disclaimer

Conflict of interest statement

RS is a consultant in Medtronic, Replimune, Cook Regentec, and Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Illustration of the mechanism underlying intratumoral cancer immunotherapy. Reproduced without change from Senders et. al. (17) (HIT-IT = human intratumoral immunotherapy, Ag, antigen).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Esfahani K, Roudaia L, Buhlaiga N, del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol (2020) 27(12):87–97. doi: 10.3747/co.27.5223 - DOI - PMC - PubMed
    1. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. (2006), 297–339. doi: 10.1016/S0065-2776(06)90008-X - DOI - PMC - PubMed
    1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) (2020) 12(3):738. doi: 10.3390/cancers12030738 - DOI - PMC - PubMed
    1. Ventola CL. Cancer immunotherapy, part 3: Challenges and future trends. P T (2017) 42(8):514–21. - PMC - PubMed
    1. Kelly CM, Antonescu CR, Bowler T, et al. . Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab. JAMA Oncol (2020) 6(3):402. doi: 10.1001/jamaoncol.2019.6152 - DOI - PMC - PubMed

Substances